This site uses technical cookies and profiling third party cookies to offer a better user experience; third party cookies require your consent. By continuing to browse the site, clicking or tapping the screen, scrolling the web page or closing this banner, you are agreeing to our use of cookies. For further information or opt out options.
IMA is loading
Post published on 21/07/2017

The evolution of automated machines and of the manufacturing process at the service of new frontiers in the world of pharmaceutics

Satisfying the right to health is one of the key contributors to quality of life on our planet. The human species, as all animal species, contract many diseases, which thanks to scientific research can now be controlled and eradicated.

One of the indicators of this continuing battle is the global pharmaceutical market trend. Indeed, this market is in constant growth, expected to reach 1.3 trillion Euro in 2019 (according to WHO).

Naturally, we are all aware of the need for greater commitment, especially in order to ensure access to medical care in the less developed regions of the world as well as among the poor, also those residing in the more developed countries.

The experience acquired by IMA – a company that has always supported those involved in drug research and production – helps us detect healthcare trends, or rather, capture everything we need in order to guide us in designing and producing future IMA automated machines for the pharmaceutical market.

In a word, the evolution in this critical sector is substantially driven by:

  • Specialised markets which focus on new chemical entities (NCEs) that are about to enter the market.
  • Precision medicine for disease prevention and treatment, which is more attentive to patients’ genetic diversity, living environment and lifestyle.
  • Development of biosimilar biological products, the new generation of more effective and customised biological drugs.
  • Development of drugs for curing central nervous system diseases, general chronic brain diseases and psychiatric disorders.
  • Patient-centric revolution which seeks to empower the patient and make him or her a more active participant in the medical treatment.
  • Growth in the production volumes of generic drugs, which are fundamental for treating and preventing the most common and widespread diseases. In an increasingly populated world the availability and access to medicines will be the benchmark of the quality of life.

Naturally, each pharmaceutical producer is bound to determine its own priorities when devising a strategy for achieving maximum success in the global markets.

We at IMA must follow and anticipate this process, a challenge we fully embrace and are committed to win by listening to customers’ demands and providing unique solutions.

In this evolutionary process, interacting with our customers is essential, and is part of our tradition of success.

Giovanni Pecchioli
Pharma Business CEO